How to buy UroGen Pharma stock

UroGen Pharma Ltd is a biotechnology business based in the US. UroGen Pharma shares (URGN) are listed on the NASDAQ and all prices are listed in US Dollars. UroGen Pharma employs 187 staff and has a trailing 12-month revenue of around 0.00.

UroGen Pharma share price

Use our graph to track the performance of URGN stocks over time.

UroGen Pharma shares at a glance

• Key figures

Information last updated 2021-03-10.

52-week range	$13.12 - $30.89
50-day moving average	$22.42
200-day moving average	$21.30
Wall St. target price	$41.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-4.89

Buy UroGen Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy UroGen Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of UroGen Pharma Ltd by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

UroGen Pharma financials

Revenue TTM	$3.8 million
Gross profit TTM	$18,000
Return on assets TTM	-45.25%
Return on equity TTM	-82.63%
Profit margin	0%
Book value	$5.46
Market capitalisation	$429.5 million

TTM: trailing 12 months

Shorting UroGen Pharma shares

There are currently 2.8 million UroGen Pharma shares held short by investors – that's known as UroGen Pharma's "short interest". This figure is 1.5% up from 2.7 million last month.

There are a few different ways that this level of interest in shorting UroGen Pharma shares can be evaluated.

UroGen Pharma's "short interest ratio" (SIR)

UroGen Pharma's "short interest ratio" (SIR) is the quantity of UroGen Pharma shares currently shorted divided by the average quantity of UroGen Pharma shares traded daily (recently around 176670.60702875). UroGen Pharma's SIR currently stands at 15.65. In other words for every 100,000 UroGen Pharma shares traded daily on the market, roughly 15650 shares are currently held short.

However UroGen Pharma's short interest can also be evaluated against the total number of UroGen Pharma shares, or, against the total number of tradable UroGen Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case UroGen Pharma's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 UroGen Pharma shares in existence, roughly 130 shares are currently held short) or 0.1554% of the tradable shares (for every 100,000 tradable UroGen Pharma shares, roughly 155 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against UroGen Pharma.

Find out more about how you can short UroGen Pharma stock.

UroGen Pharma share dividends

We're not expecting UroGen Pharma to pay a dividend over the next 12 months.

UroGen Pharma share price volatility

Over the last 12 months, UroGen Pharma's shares have ranged in value from as little as $13.1184 up to $30.89. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while UroGen Pharma's is 1.2316. This would suggest that UroGen Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

UroGen Pharma overview

UroGen Pharma Ltd. , a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd.

Frequently asked questions

• What percentage of UroGen Pharma is owned by insiders or institutions?

  Currently 12.737% of UroGen Pharma shares are held by insiders and 75.179% by institutions.

• How many people work for UroGen Pharma?

  Latest data suggests 187 work at UroGen Pharma.

• When does the fiscal year end for UroGen Pharma?

  UroGen Pharma's fiscal year ends in December.

• Where is UroGen Pharma based?

  UroGen Pharma's address is: 400 Alexander Park, Princeton, NJ, United States, 08540

• What is UroGen Pharma's ISIN number?

  UroGen Pharma's international securities identification number is: IL0011407140

• What is UroGen Pharma's CUSIP number?

  UroGen Pharma's Committee on Uniform Securities Identification Procedures number is: M96088105